Mohammad Mansoor, PhD, a pioneer in medical genomics, takes a dive into genes and gene expression in regard to viruses. Dr. Mansoor provides details into how genetic variability may influence COVID-19 susceptibility. He highlights two specific genes, the ACE2 gene and the TEMPRSS2 gene, which have generated some attention and are being researched for their potential roles. He further explains why genes are much more complex and why we must look at the whole picture to understand the functionality of gene expression. He also discusses the importance of cellular methylation and how methylation plays a landmark roll in anti-inflammation.
Mohammad Mansoor, PhD is the President and CSO of The DNA Company, a leading and innovative provider of comprehensive Functional Genomics testing, consulting, and personalized health solutions.
Dr. Mansoor is widely regarded as a pioneer in medical genomics and has been the recipient of multiple academic and industry awards. He is the holder of several patents in the general fields of molecular diagnostics and genomics research and is one of the most sought-after national and international conference speakers in the genre of personalized medicine.
Prior to his role at The DNA Company, Dr. Mansoor was Founder and President of ManaGene, CEO of Combimatrix, Director of Genomics at Quest Diagnostics, and Director of Research and Development at Spectral Genomics, one of the industry’s first commercial genomic microarray developers spun out of Baylor College of Medicine.
Dr. Mansoor maintains an active clinical practice as a genomics consultant to some of the leading executive health clinics in Canada and abroad. Dr. Mohammed has served on the Canadian Board of Autistic Research and is a consultant to the world-renowned Toronto Center of Applied Genomics. He is also the Genomicist-in-Residence for the Autism Hope Alliance.